Gut Hormones Restrict Neurodegeneration in Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
IntroductionParkinson's disease is the most common neurodegenerative movement disorder and the second most common neurological disorder behind Alzheimer's disease in today's society.It is a progressive disorder that affects more than 1% of people older than 60.Cardinal features of Parkinson's disease include motor dysfunction such as rigidity, resting tremor, postural instability and bradykinesia.These debilitating symptoms manifest due to the massive loss of dopamine in the striatum, the nerve terminal region of dopamine neurons are located in the substantia nigra pars compacta (SNpc).This anatomical circuit is known as the nigrostriatal pathway and plays a critical role in fine tuning motor functions.At present there are only a few known monogenic mutations accelerating the onset of Parkinson's disease, therefore most cases are considered sporadic and develop as a complex polygenic interaction with age and environment.Although the pathogenesis of Parkinson's disease is largely unknown, mitochondrial dysfunction, oxidative stress, intracellular protein accumulation (Lewy Bodies containing α-synuclein) and abnormal protein degradation all play a key role in disease progression.Because loss of dopamine in the striatum causes motor dysfunction in Parkinson's disease, dopamine supplementation can be used to alleviate motor symptoms but this is only a temporary solution as the efficacy diminishes with age and as the disease progresses.There are no known therapies that halt or reduce the progression of the disease, largely because the cause of Parkinson's disease remains enigmatic.Parkinson's disease also causes symptoms in other parts of the nervous system.Constipation and gastrointestinal (GI) problems are often some of the earliest symptoms, well before the presence of dopamine dysfunction, and post mortem studies in Parkinson's disease patients identified protein accumulation in the enteric nervous system of the GI tract [1].This 'Braak's hypothesis' suggests protein accumulation in enteric neurons spreads in a retrograde manner to the brain through the dorsal motor nucleus of the vagus and triggers Parkinson's disease.Braak observed in post mortem tissue that patients with presymptomatic Parkinson's disease had protein aggregation in the peripheral nervous system but not the central nervous system [1].Protein aggregation ascended into the central nervous system and correlated with the development of motor dysfunction.This observation shows that the topographic ascending lesion pattern resembles a falling row of www.intechopen.comAdvanced Understanding of Neurodegenerative Diseases 270 dominos and prompts the question; does Parkinson's disease originate outside the central nervous system?Recent evidence supports the hypothesis that GI abnormalities, which precede central nervous system changes, trigger Parkinson's disease.For example, mice expressing mutant α-synuclein in gut enteric neurons exhibited extensive GI dysfunction followed by motor abnormalities [2].Moreover, low doses of rotenone, a compound found in pesticides that causes Parkinson's-like conditions, produced GI disturbances and enteric neuronal αsynuclein aggregates in rats before neuronal protein aggregation [3,4].These studies, taken together with the early GI disturbances in humans, clearly implicate the GI system in the pathogenesis of Parkinson's disease.The stomach and intestines comprise the GI 'digestive' system, which produces a number of hormones to aid energy metabolism, digestion and nutrient uptake into the circulation.Despite the fact that evidence suggests GI dysfunction triggers Parkinson's disease, little is known about gastrointestinal hormones in Parkinson's disease.This chapter examines how gut hormones influence the nigrostriatal dopamine system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expression of ghrelin receptor mRNA in the rat and the mouse brain
Zigman, J. M., Jones, J. E., Lee, C. E., Saper, C. B., & Elmquist, J. K. (2006) · The Journal of Comparative Neurology · doi:10.1002/cne.20823 · Cited by 1,074
Zong, H., Ren, J. M., Young, L. H., Pypaert, M., Mu, J., Birnbaum, M. J., & Shulman, G. I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252625599 · Cited by 1,036
Abizaid, A., Liu, Z.-W., Andrews, Z. B., Shanabrough, M., Borok, E., Elsworth, J. D., Roth, R. H., Sleeman, M. W., Picciotto, M. R., Tschöp, M. H., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29867 · Cited by 984
Leptin Receptor Signaling in Midbrain Dopamine Neurons Regulates Feeding
Hommel, J. D., Trinko, R., Sears, R. M., Georgescu, D., Liu, Z.-W., Gao, X.-B., Thurmon, J. J., Marinelli, M., & DiLeone, R. J. (2006) · Neuron · doi:10.1016/j.neuron.2006.08.023 · Cited by 902
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Ghrelin controls hippocampal spine synapse density and memory performance
Diano, S., Farr, S. A., Benoit, S. C., McNay, E. C., da Silva, I., Horvath, B., Gaskin, F. S., Nonaka, N., Jaeger, L. B., Banks, W. A., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1656 · Cited by 828
Resveratrol stimulates AMP kinase activity in neurons
Dasgupta, B., & Milbrandt, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610068104 · Cited by 723
UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals
Andrews, Z. B., Liu, Z.-W., Walllingford, N., Erion, D. M., Borok, E., Friedman, J. M., Tschöp, M. H., Shanabrough, M., Cline, G., Shulman, G. I., et al. (2008) · Nature · doi:10.1038/nature07181 · Cited by 710
Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency
López-Lluch, G., Hunt, N., Jones, B., Zhu, M., Jamieson, H., Hilmer, S., Cascajo, M. V., Allard, J., Ingram, D. K., Navas, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510452103 · Cited by 699
The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress
Lutter, M., Sakata, I., Osborne-Lawrence, S., Rovinsky, S. A., Anderson, J. G., Jung, S., Birnbaum, S., Yanagisawa, M., Elmquist, J. K., Nestler, E. J., et al. (2008) · Nature Neuroscience · doi:10.1038/nn.2139 · Cited by 644
Cited by
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
The Association Between the Gut Microbiota and Parkinson’s Disease, a Meta-Analysis
Shen, T., Yue, Y., He, T., Huang, C., Qu, B., Lv, W., & Lai, H.-Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.636545 · Cited by 219
Johnson, M. E., Stringer, A., & Bobrovskaya, L. (2018) · NeuroToxicology · doi:10.1016/j.neuro.2018.02.013 · Cited by 122
Mihaila, D., Donegan, J., Barns, S., LaRocca, D., Du, Q., Zheng, D., Vidal, M., Neville, C., Uhlig, R., & Middleton, F. A. (2019) · PLOS ONE · doi:10.1371/journal.pone.0218252 · Cited by 94
Metadata
- Authors
- Bayliss, J., Stark, R., Reichenbach, A., & B., Z.
- Venue
- Advanced Understanding of Neurodegenerative Diseases
- Publisher
- InTech
- Published
- 2011-12-16
- OpenAlex
- W1543535048
- Cited by
- 5
- References
- 29
- FWCI
- 0.89
- Type
- book chapter
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.